Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03185481 · ClinicalTrials.gov registry record · Phase 2
Safety and Tolerability of PF-06649751 in Parkinson's Disease Patients With Motor Fluctuations
A Phase 2 study, sponsored by Pfizer.
- Terminated
- Registry status
- Phase 2
- Development phase
- 5
- Enrollment target
NCT03185481 is a Phase 2 study that was terminated before completion, run by Pfizer. The registered enrollment target is 5 participants.
The verdict
NCT03185481, a Phase 2 study, was terminated before completion, sponsored by Pfizer.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 5 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate the long term safety and tolerability of PF-06649751 in Parkinson's disease patients who experience motor-fluctuations.
Interventions
- DRUG 1 mg QD to 15 mg QD PF-06649751
- DRUG 3 mg QD to 15 mg QD PF-06649751
- DRUG 7 mg QD to 15 mg QD PF-06649751
- DRUG 15 mg QD PF-06649751
- DRUG 1 mg QD to 7 mg QD PF-06649751 (if de-escalated in parent study)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 5 participants |
| Start Date | 2017-07-06 |
| Est. Completion | 2017-10-25 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03185481
The ClinicalTrials.gov registry entry for NCT03185481 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 5 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Pfizer, which has 1,845 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which 1 mg QD to 15 mg QD PF-06649751 is the first listed.
NCT03185481 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03185481 about?
NCT03185481 is a clinical study titled "Safety and Tolerability of PF-06649751 in Parkinson's Disease Patients With Motor Fluctuations". The purpose of this study is to evaluate the long term safety and tolerability of PF-06649751 in Parkinson's disease patients who experience motor-fluctuations.
What is the current status of trial NCT03185481?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 5 participants. The study started on 2017-07-06. Estimated completion is 2017-10-25.
What interventions are being tested in trial NCT03185481?
The interventions under investigation include: 1 mg QD to 15 mg QD PF-06649751 (DRUG), 3 mg QD to 15 mg QD PF-06649751 (DRUG), 7 mg QD to 15 mg QD PF-06649751 (DRUG), 15 mg QD PF-06649751 (DRUG), 1 mg QD to 7 mg QD PF-06649751 (if de-escalated in parent study) (DRUG).
Who is sponsoring clinical trial NCT03185481?
This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.